A recent Gastroenterology digest,
as sent to subscribers

Study Type: Translational mechanistic study (human tissue analysis with genetically engineered mouse models)

Key Question: Does epithelial FOXP3 drive early pancreatic fibrosis and carcinogenesis via a glycosylation-dependent IL-6 signalling mechanism?

Key Findings:

• Epithelial FOXP3 (E-FOXP3) transactivates GALNT1, which O-glycosylates IL-6 at threonine-165, enabling its secretion and activation of pancreatic stellate cells via gp130/MAPK-ERK signalling
• Epithelial-specific FOXP3 knockout attenuated fibrosis and delayed PanIN progression; knock-in induced spontaneous stromal activation and accelerated neoplasia
• A fasting-mimicking diet suppressed the E-FOXP3–GALNT1 axis, reducing IL-6 glycosylation and pancreatic fibrosis in vivo

Clinical Relevance: Identifies a druggable early-stage fibrocarcinogenic pathway in PDAC — a cancer with persistently poor UK outcomes — and raises interest in dietary intervention as a stromal-targeting strategy.

Limitations: Predominantly preclinical; human tissue data are correlative, with no clinical intervention evidence yet available.

Study Type: Prospective multicentre RCT

Key Question: Does proactive home-based faecal calprotectin (FC) monitoring every two months reduce symptomatic flares in UC patients in remission?

Key Findings:

• No significant difference in risk of symptomatic flare between intervention and control arms (HR 1.05, 95% CI 0.79–1.40); 32% flared in both groups over 18 months
• No differences in secondary endpoints including healthcare utilisation, medication use, or quality of life
• Among the 88 patients whose therapy was changed following a confirmed elevated FC, flare frequency was numerically lower (49% vs 55%) but did not reach statistical significance

Clinical Relevance: This challenges the assumption that FC home monitoring alone improves outcomes in UC; without a protocolised treatment escalation pathway, routine FC surveillance does not appear to prevent flares in NHS remission-monitoring programmes.

Limitations: Absence of a mandatory treatment escalation protocol when FC was elevated likely significantly undermined the intervention's potential efficacy.

Study Type: Multicentre cohort study with mechanistic validation (human exome sequencing, organoid models, knock-in/knockout mouse and zebrafish models, transcriptome analysis)

Key Question: Do rare loss-of-function variants in *BIRC3* cause monogenic Crohn's disease through dysregulated RIPK1-mediated intestinal epithelial cell death?

Key Findings:

• Rare damaging *BIRC3* variants identified in 14 patients across 10 unrelated families, with onset ranging from infancy to adulthood
• *BIRC3* deficiency impairs RIPK1 ubiquitylation, driving autophosphorylation and excess epithelial apoptosis/necroptosis, with spontaneous colitis observed in *ciap1−/+* zebrafish
• Pharmacological RIPK1 inhibition and caspase inhibition attenuated inflammation in both organoid and murine knock-in models

Clinical Relevance: This establishes *BIRC3* as a novel monogenic cause of CD relevant across all ages, potentially informing genetic workup of treatment-refractory or very-early-onset IBD in NHS practice, and identifies RIPK1 as a tractable therapeutic target.

Limitations: Patient numbers are small (n=14), limiting genotype–phenotype characterisation and assessment of penetrance.

Study Type: Cohort study with functional immunological analysis

Key Question: What is the serological and functional significance of preS1 antigen and anti-preS1 IgG in chronic hepatitis B, including their relationship to viral control after stopping nucleos(t)ide analogues (NUCs)?

Key Findings:

• PreS1 antigen levels were highest in HBeAg-positive patients and correlated positively with HBV DNA, HBsAg, and HBeAg
• Anti-preS1 IgG inversely correlated with HBV DNA and demonstrated potent HBV/HDV neutralising activity by blocking preS1-NTCP binding, with dominant epitopes mapping to the NTCP-binding domain
• High baseline anti-preS1 IgG was associated with sustained virological suppression following NUC discontinuation in 51 patients

Clinical Relevance: Anti-preS1 IgG may serve as a clinically useful biomarker to identify CHB patients most likely to achieve sustained off-therapy remission — a key decision point in NUC stopping-rule discussions increasingly relevant to UK hepatology practice.

Limitations: The NUC discontinuation cohort was small (n=51), limiting the statistical robustness of the off-therapy suppression findings.

Study Type: Translational mechanistic study (human tissue samples, murine models, and in vitro experimentation)

Key Question: How does pancreatic fibrosis activate Schwann cells within the tumour microenvironment of pancreatic ductal adenocarcinoma?

Key Findings:

• Stiffer perineural stroma correlates with greater Schwann cell (SC) activation (c-Jun phosphorylation) in human PDAC samples and murine models
• Mechanical force induces SC activation via nuclear compression triggering non-canonical AP-1/c-Jun signalling, involving phospholipase A2, independently of cancer cell signalling
• Fibrosis alone (without malignant cells) is sufficient to activate SCs, and SCs demonstrate greater mechanosensitivity than PDAC cells themselves

Clinical Relevance: Identifies a stroma–nerve interaction as a tractable therapeutic target in PDAC, a disease with persistently poor outcomes, potentially relevant across fibrotic pancreatic conditions managed within NHS hepatopancreaticobiliary services.

Limitations: Mechanistic findings are predominantly preclinical; direct therapeutic applicability in humans requires further validation.

Study Type: Preclinical mechanistic study (in vitro and orthotopic mouse models with human cohort analysis)

Key Question: Does targeting the kinase NEK9 overcome immunotherapy resistance in HCC by remodelling the tumour microenvironment?

Key Findings:

• NEK9 overexpression in HCC correlated with poor survival, reduced intratumoral CD8+ T cell infiltration, and increased MDSCs in human cohorts
• Mechanistically, NEK9 phosphorylates TRIM28/USP46, stabilising NF-κB2 and driving PD-L1 and CXCL1 transcription — promoting T cell dysfunction and MDSC recruitment
• Two novel NEK9 inhibitors (MIPO, FPTP) demonstrated strong synergy with anti-PD-L1 therapy in vivo, enhancing CD8+ T cell effector function and tumour suppression

Clinical Relevance: ICI monotherapy yields modest response rates in HCC; NEK9 inhibition represents a potential combinatorial strategy to sensitise tumours to checkpoint blockade in a disease where treatment options remain limited.

Limitations: Findings are entirely preclinical — no human pharmacokinetic, safety, or efficacy data exist for the identified inhibitors.

Study Type: Systematic review and network meta-analysis of RCTs

Key Question: Which gut-brain neuromodulators and brain-gut behavioural therapies are most efficacious for IBS?

Key Findings:

• SNRIs ranked highest (P-score 0.95; RR 0.49, 95% CI 0.32–0.75) for global symptom improvement, though based on only six trials (387 patients) all at uncertain/high risk of bias
• TCAs ranked second (RR 0.60, 95% CI 0.43–0.85; 15 trials, 1519 patients); dynamic psychotherapy/emotional processing ranked third (RR 0.62, 95% CI 0.44–0.87)
• CBT, disease self-management, SSRIs, and gut-directed hypnotherapy were all superior to waiting list control

Clinical Relevance: Directly supports prescribing and referral decisions in NHS IBS management, reinforcing NICE guidance favouring TCAs and psychological therapies where access exists.

Limitations: Evidence certainty was low or very low for most comparisons, with possible publication bias and no trials at low risk of bias for the top-ranked treatment (SNRIs).

Study Type: International multicentre retrospective cohort study

Key Question: Can preoperative MRI-based models predict very early HCC recurrence (within 1 year) after curative resection of single BCLC 0/A HCC?

Key Findings:

• Two models (MERP-pre: AFP, tumour size, peritumoral hypoenhancement, blood products; MERP-post: substituting MVI for tumour size) outperformed existing staging systems and IMbrave050 criteria across all validation cohorts (C-indexes 0.685–0.790 vs 0.524–0.682; p<0.001–0.046)
• Both models significantly improved risk reclassification (NRI 0.004–0.372) and stratified patients into distinct 1-year RFS groups across Eastern, Western, and CT-based cohorts
• Low-risk MERP-pre tumours showed non-proliferative biology, increased lipid catabolism, and immunoactive microenvironments

Clinical Relevance: For UK hepatobiliary MDTs, these models could improve preoperative risk stratification to guide adjuvant therapy decisions and surveillance intensity following HCC resection.

Limitations: Retrospective design with predominantly Asian patient cohorts limits direct generalisability to UK/Western populations.